BridGene nets another Takeda deal amid plans to raise more funding and go public

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences.

The Tokyo-based drugmaker announced Tuesday that it is once again …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

New migraine drug atogepant shows quick relief

A drug recently approved to prevent migraine may start working right away, according to a study published in the December 23, 2024, online issue of

December 24, 2024

Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to Eliminate Tumor Cells from Surgical Blood – Biotech Investments

EQS-News: Lindis Blood Care GmbH / Key word(s): Study Lindis Blood Care Announces Last Patient Out in Multicenter Clinical Certification Study REMOVE with CATUVAB® to

December 21, 2023

Study highlights advantages of syphilis self-testing: convenience, privacy, and rapid results

Researchers performed a meta-analysis on the utility of syphilis self-testing (SST).

July 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.